Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

the standard of care. The study found:

-- Up to 81 percent of those patients treated with R1626 1500 mg (twice-

daily) + PEGASYS + COPEGUS had an undetectable HCV viral load by week

four (mean reduction of 5.2 log10 IU/mL)

-- ALT, a liver enzyme, normalized in approximately 50 percent of patients

in R1626 treatment groups

-- Most reported adverse events were mild to moderate. Dose dependent,

reversible grade four neutropenia was observed in the R1626 arms (36

percent in patients receiving R1626 1500 mg + PEGASYS + COPEGUS), and

was the main reason for dose reduction and discontinuation

Lack of Resistance

According to a second presentation at the conference, resistance to R1626 was not identified following intensive testing for either two weeks of treatment with R1626 as monotherapy, or in patients treated with R1626 for four weeks in combination with the standard of care. These findings suggest that there is a high barrier to the development of resistance to R1626 in vivo.

Start of Phase IIb Trial

R1626 is being progressed into Phase IIb study, called POLI 1, to further investigate the new treatment regimens of R1626, in combination with standard or lower dose of PEGASYS and standard dose of COPEGUS. This Phase IIb trial is now open and enrolling patients in eight countries, including the United States. More information about R1626 and the clinical studies can be found on http://www.roche-trials.com.

"As a clinician, I am excited by the high rates of viral negativity that were observed after four weeks of treatment with R1626 in combination with the standard of care. The design of the Phase IIb study should enable us to find the doses of R1626, PEGASYS and COPEGUS that achieve the appropriate balance between safety and efficacy," said Dr. David Nelson, Director of Hepatology and Liver Transplantation at the
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014  Chuma Holdings, Inc. (OTCBB:CHUM) ... and turnkey support services for the lawfully organized ... processed and approved the Company,s name and symbol ... Corporation will be known as Chuma Holdings, Inc. ... through a merger with the Company,s wholly-owned subsidiary, ...
(Date:8/29/2014)... , Aug. 29, 2014  A Boston Scientific ... study on stent removability and preliminary long term ... published in the August issue of the peer-reviewed ... 1 is being conducted in 11 countries ... covered self-expanding metal stents (FCSEMS) after extended indwell ...
(Date:8/29/2014)... Research and Markets has announced ... Report, 2014-2017" report to their offering. ... of reimbursement for medical expenses, the Chinese orthopedic instrument ... presenting a CAGR of 19.2% during 2009-2013. Trauma products, ... of orthopedic instruments in China , ...
Breaking Medicine Technology:CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4China Orthopedic Instrument Industry Report, 2014-2017 2
... Patch Formulation May Provide New Option for Clinicians Concerned ... Systemic Exposure When ... Alpharma Inc. (NYSE: ALO ),a leading global ... presented this week at the American Pain Society annual,meeting ...
... Inc.,(Nasdaq: ARNA ) announced today that Taisho ... of a drug candidate under a GPCR-focused,partnership with ... drug candidate is a novel oral compound intended ... "We are very happy to see our long-standing ...
Cached Medicine Technology:Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 4Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 5Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 6Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 7Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 2Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 3
(Date:9/1/2014)... September 01, 2014 The B-cell non-Hodgkin’s ... across six major markets (the US, France, Italy, Germany, ... to $5.41 billion by 2018. , The competitive landscape ... Italy, Germany, Spain and the UK is poised to ... management of the four largest B-cell NHL indications, which ...
(Date:9/1/2014)... Barcelona, Spain Monday 1 September 2014: Daily fruit ... up to 40%, according to research presented at ESC ... The findings from the seven year follow-up study of ... found that the more fruit people ate, the more ... "CVD, including ischaemic heart disease (IHD) and stroke, is ...
(Date:9/1/2014)... As well as having completed the ... pursuing counselor certification in Louisiana. , "I ... training program as well as the Counselor training ... personally and professionally. I am not only dedicated ... to do so. As a Non Violent Crisis ...
(Date:9/1/2014)... 2014 BCC Research ( http://www.bccresearch.com ) ... TECHNOLOGIES AND GLOBAL MARKETS , the global market for ... and is expected to reach $38.7 million in 2014. ... by 2019, which is equivalent to 64.9% compound annual ... transport (RMT) segment is forecasted to grow at a ...
(Date:9/1/2014)... Oakdale, MN (PRWEB) September 01, 2014 In honor ... place on Aug. 22, Animal Emergency & Referral Center of Minnesota ... veterinarian visits a priority for their cats. , Many people don’t ... “it’s too much of a hassle,” but they wouldn’t decide not ... no signs of a cavity. The same goes for pets. Just ...
Breaking Medicine News(10 mins):Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 2Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 3
... GAITHERSBURG, Md., Dec. 5 Panacea Pharmaceuticals, ... a fully human sequence,monoclonal antibody against HAAH ... in collaboration with the Massachusetts Institute of ... efficacy in animal,models of cancer. Having a ...
... publication Head and Neck Pathology. Published under the Humana ... North American Society for Head and Neck Pathology (NASHNP). ... December 2007, it will be available free of charge for ... Pathology will present scholarly papers, reviews and case reports that ...
... new ways of tweaking the molecular structure of antibiotics ... fight against powerful super bugs. , The work, led ... geneticist Professor Colin Smith, is published online today (Wednesday ... of the Journal of the American Chemical Society. , ...
... Clinical study compares rotational stability of two differently designed, ... of every day viewing conditions, JACKSONVILLE, Fla., Dec. ... vision may sometimes fluctuate during the day, the answer,may ... new clinical study,demonstrates. The findings, say researchers, may be ...
... Inc., a,medical device company developing endovascular devices for ... announced,the appointment of Christopher R. Barys to the ... to FlowCardia with over 16 years of,experience in ... in the,interventional endovascular products field., Most recently, ...
... Alliance, the leading,management consulting firm specializing in the ... Vice President,of the firm,s Business Development practice, will ... at the Strategic Research,Institute,s (SRI) Pharma & Biotech ... on December 10-11, 2007, at the San Diego ...
Cached Medicine News:Health News:Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product 2Health News:Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product 3Health News:Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product 4Health News:Scientists strike blow in superbugs struggle 2Health News:Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye 2Health News:Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye 3Health News:Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye 4Health News:Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye 5Health News:FlowCardia, Inc. Appoints Chris Barys Senior VP, Sales 2Health News:Campbell Alliance Business Development Practice Leader to Co-Chair and Keynote at SRI Pharma Licensing Summit 2Health News:Campbell Alliance Business Development Practice Leader to Co-Chair and Keynote at SRI Pharma Licensing Summit 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: